Going global

Magnetic blood filter granted US patent

June 18, 2019


Medical device company MediSieve Ltd, which has developed the concept of magnetic blood filtration to remove disease-causing agents from the blood, has been awarded a patent for its product in America. 

The technology can potentially transform the treatment of blood-borne diseases, including sepsis, leukaemia and malaria, in a process that is similar to dialysis. 

The patent for MediSieve’s 
magnetic blood filter has now been granted in the United States. With patent number US10265457B2, it’s titled ‘Magnetic filter apparatus and method’ and covers the company’s filter, magnet and system for extracting magnetic components such as malaria-infected cells from the bloodstream. The patent has also been filed under PCT and is pending in Europe, Canada, Japan, China, India, Brazil and Australia. 

Founder of MediSieve, Dr George Frodsham, said:

“This is an important step – there’s a big difference between filing a patent and having it granted. Having patent protection is important to protect our technology and market share. The US is still the world’s biggest healthcare market, and this cements our position as the global leader in magnetic blood filtration. It puts us in a strong position against any potential competitors, and is a milestone validating the innovative nature of our unique technology. The next step is for the other patents to come through, and we expect this to start happening soon.” 

The patent was granted in late April, and expires in 2037. It was originally filed in September 2016 through patent attorney Tom Turano at Boston-based K&L Gates. 

MediSieve’s magnetic blood filter removes malaria infected red blood cells by passing blood through a strong magnetic filter, which captures the infected cells by exploiting their naturally occurring magnetic properties. The rest of the blood is then returned to the infected patient. The same device can be used to capture other magnetic components, namely MediSieve’s magnetic particles, designed to bind to specific targets in blood to enable their removal.

The company aims to launch their malaria treatment in 2021. The first clinical trials are planned for later in 2019, before Phase two trials take place in malarial areas. The patent news comes after MediSieve announced that it has been awarded two grants from Innovate UK, worth some £1.56m in all. 

MediSieve was established in 2015 as an independent company and has its origins in University College London. The company is based in London’s White City, at the Imperial College Translation and Innovation Hub

For more information about MediSieve, visit 

News & Analysis

by Editor